Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE ...

The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to enhance antitumor responses while minimizing liver toxicity by focusing activation within the tumor ...

To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal ...